Cell-derived vesicles as diagnostic instrument for prostate cancer.
- Conditions
- prostate cancer
- Registration Number
- NL-OMON28556
- Lead Sponsor
- Academisch Medisch Centrum Amsterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
Healthy volunteers:
Adult male not related to the Urology department ≤ 40 years old. Informed consent signed.
Exclusion Criteria
Healthy volunteers:
Clinical signs of prostate diseases, medical or surgical therapy for prostate disease.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the concentration of tdEVs in plasma and urine in PCa patients and assess whether a relationship exists to disease state.
- Secondary Outcome Measures
Name Time Method 1.To determine whether (elevated levels of) prostate-derived EVs are detectable in plasma and/or urine samples from mCRPC patients compared to both healthy controls as well as controls with elevated PSA.<br /><br>2.To determine whether (elevated levels of) prostate-derived EVs are detectable in plasma and/or urine samples from early stage PCa patients to both healthy controls as well as controls with elevated PSA.<br /><br>3.To identify mRNAs that differentiate PCa from controls <br /><br>4.To assess whether a correlation exists between ctDNA, tdEV, mRNA.<br /><br>5.To verify that any PCa associated markers from secondary objectives 1-4 are reduced to approximately the control level after prostatectomy.